mozavaptan has been researched along with tetradecanoylphorbol acetate in 1 studies
| Studies (mozavaptan) | Trials (mozavaptan) | Recent Studies (post-2010) (mozavaptan) | Studies (tetradecanoylphorbol acetate) | Trials (tetradecanoylphorbol acetate) | Recent Studies (post-2010) (tetradecanoylphorbol acetate) |
|---|---|---|---|---|---|
| 165 | 8 | 24 | 31,050 | 61 | 2,217 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirai, S; Kosaka, K; Mizuno, K; Nishioka, N; Ohno, S; Osada, S; Suzuki, A | 1 |
1 other study(ies) available for mozavaptan and tetradecanoylphorbol acetate
| Article | Year |
|---|---|
Wortmannin inhibits the activation of MAP kinase following vasopressin V1 receptor stimulation.
Topics: Androstadienes; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Calcium-Calmodulin-Dependent Protein Kinases; Cells, Cultured; Deamino Arginine Vasopressin; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Fibroblasts; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Piperidines; Quinolones; Rats; Receptors, Vasopressin; Signal Transduction; Tetradecanoylphorbol Acetate; Wortmannin | 1995 |